Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL84 inhalation study in adults with cystic fibrosis carrying the CFTR 3849+10kb C>T mutation
NL-OMON59048Phase 2Suspended
- Sponsor
- SpliSense
- Start
- Nov 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SPL84 in cystic fibrosis (CF) (4 cohorts), sponsored by SpliSense. Primary endpoints: Adverse events and serious adverse events, Safety assessments and 2 more. Started Nov 2024; status: suspended.
02
Drugs
SPL84
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON59048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59048.